全文获取类型
收费全文 | 6279篇 |
免费 | 303篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 310篇 |
妇产科学 | 69篇 |
基础医学 | 601篇 |
口腔科学 | 128篇 |
临床医学 | 539篇 |
内科学 | 1324篇 |
皮肤病学 | 139篇 |
神经病学 | 380篇 |
特种医学 | 210篇 |
外科学 | 1332篇 |
综合类 | 93篇 |
一般理论 | 7篇 |
预防医学 | 254篇 |
眼科学 | 310篇 |
药学 | 339篇 |
中国医学 | 17篇 |
肿瘤学 | 513篇 |
出版年
2024年 | 6篇 |
2023年 | 60篇 |
2022年 | 120篇 |
2021年 | 263篇 |
2020年 | 118篇 |
2019年 | 196篇 |
2018年 | 210篇 |
2017年 | 163篇 |
2016年 | 165篇 |
2015年 | 196篇 |
2014年 | 276篇 |
2013年 | 309篇 |
2012年 | 488篇 |
2011年 | 493篇 |
2010年 | 314篇 |
2009年 | 230篇 |
2008年 | 392篇 |
2007年 | 412篇 |
2006年 | 401篇 |
2005年 | 394篇 |
2004年 | 355篇 |
2003年 | 269篇 |
2002年 | 241篇 |
2001年 | 63篇 |
2000年 | 61篇 |
1999年 | 50篇 |
1998年 | 46篇 |
1997年 | 39篇 |
1996年 | 41篇 |
1995年 | 36篇 |
1994年 | 23篇 |
1993年 | 17篇 |
1992年 | 22篇 |
1991年 | 18篇 |
1990年 | 14篇 |
1989年 | 15篇 |
1988年 | 15篇 |
1987年 | 14篇 |
1986年 | 12篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1976年 | 5篇 |
1974年 | 11篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1970年 | 6篇 |
排序方式: 共有6649条查询结果,搜索用时 15 毫秒
1.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
2.
3.
4.
5.
Neetu Radhakrishnan M.D. Chong. H. Park M.D. Barry M. Kaplan M.D. F.A.C.C. Rajiv Jauhar M.D. F.A.C.C. 《The International journal of angiology》2006,15(1):37-42
A 65-year-old man developed acute limb ischemia, severe abdominal wall and lower limb livedo reticularis following a coronary
angiogram. The differential diagnoses of acute limb ischemia and multiple cholesterol emboli syndrome (MCES) are discussed.
This work was performed at Long Island Jewish Medical Center, 270-05, 76th Avenue, New Hyde Park, NY 11040. 相似文献
6.
Perianal mucinous adenocarcinoma is a rare tumour which may be associated with long‐standing chronic perianal sepsis. Early diagnosis is challenging and is based on a high index of clinical suspicion and specific histological features. Definitive treatment is surgical, in the form of an abdomino‐perineal resection. We hereby describe a case of a perianal mucinous adenocarcinoma arising from long‐standing recurrent perianal fistula and complement this with a brief review of the literature pertaining in particular to the management of this condition. 相似文献
7.
Raja Kandaswamy J. Keith Melancon Ty Dunn Miguel Tan Vincent Casingal Abhinav Humar William D. Payne Rainer W. G. Gruessner David L. Dunn John S. Najarian David E. R. Sutherland Kristen J. Gillingham Arthur J. Matas 《American journal of transplantation》2005,5(6):1529-1536
We compared three maintenance immunosuppressive regimens in a rapid discontinuation of prednisone protocol. From March 1, 2001, through December 31, 2003, 239 first and second kidney transplant recipients (166 LD; 73 DD) were randomized. All recipients were treated with Thymoglobulin; all received steroids intraoperatively and for 5 days postoperatively. Randomization was to cyclosporine-mycophenolate mofetil (n = 85); high-level tacrolimus (TAC) (8-12 ng/mL)-low-level sirolimus (SRL) (3-7 ng/mL) (n = 72); or low-level TAC (3-7 ng/mL)-high-level SRL (8-12 ng/mL) (n = 82). We found no difference at 24 months between groups in patient, graft, death-censored graft, or acute rejection-free graft survival, or in kidney function. Wound complications were more common in SRL-treated recipients (p = 0.02); we found no other differences between groups in complication rates. Our data suggest that excellent patient and graft survival and low rejection rates can be obtained using a variety of maintenance protocols without prednisone. 相似文献
8.
Ashok Verma Mazin Al Khabori Rajiv Zutshi 《Indian journal of otolaryngology and head and neck surgery》2006,58(1):9-14
This is a prospective, non-randomized study to evaluate and compare the results, morbidity and surgical time for endonasal carbon-dioxide laser assisted dacryocystorhinostomy and external dacryocystorhinostomy. 70 consecutive patients of chronic dacryocystitis with nasolacrimal duct obstruction were selected for the study. 36 patients under went endonasal CO2 laser assisted dacryocystorhinostomy and 34 had external dacryocystorhinostomy. Selection of the type of operation was left to the patient's choice. All the patients had preoperative counseling and both the procedures were explained in detail with their advantages and disadvantages. Patients not willing for the external incision were selected for endonasal laser assisted dacryocystorhinostomy and others were operated via external approach. Silicone tubes were put in all the patients for three months after surgery. The final follow up was 12 months after the removal of silicone tubes. The patency of the lacrimal passage was confirmed by irrigation, and patients were questioned about their symptoms. The success rates, 12 months after removal of silicone tubes were 100% in endonasal CO2 laser assisted dacryocystorhinostomy and 88.24% in external dacryocystorhinostomy. The surgical time of endonasal laser assisted dacryocystorhinostomy was 38 minutes as compared to 62 in external dacryocystorhinostomy. Complication rate in both groups was almost equal. Thus, we came to the conclusion that Endonasal CO2 laser assisted dacryocystorhinostomy is a better surgical option to external dacryocystorhinostomy in cases of chronic dacryocystitis with nasolacrimal duct obstruction, with shorter surgical time. 相似文献
9.
Seeing the Light: Protein Theories of General Anesthesia 总被引:1,自引:0,他引:1
10.
Measuring the efficacy of antiepileptic drugs. 总被引:4,自引:0,他引:4
Clinical trials of new antiepileptic drugs (AEDs) include regulatory studies aimed at demonstrating efficacy and reasonable safety, post-marketing open-open label studies and longer term outcome studies. Regulatory trials involve a carefully selected population of patients and are conducted under rigorously standardised conditions. Data from such studies cannot often be translated into clinical practice. Pragmatic post-marketing studies using flexible dosing schedules allow clinicians to better judge the utility of the new drug in a wider population of patients with epilepsy and decide the most appropriate dosing schedules. This paper discusses some of the issues surrounding the measurement of efficacy of new AEDs in both pre- and post-marketing phases of their development. All of the newer AEDs are initially used in patients with refractory partial seizures as adjunctive treatment. These trials are generally parallel-group studies although cross-over designs have been employed. The use of placebo-control is uncontroversial in this type of study. Efficacy endpoints are generally manipulations of seizure frequency on study drug compared to control. Global outcome measures and health related quality of life scores can also be used to measure efficacy. As the standard AEDs are associated with a high rate of seizure remission in patients who receive them as monotherapy, demonstration of superior efficacy of a new agent in a comparative trial will require large numbers of patients in a design that takes into account the natural history of treated epilepsy. Comparing investigational agents to a standard AED in an 'active-control' study with demonstration of equivalent efficacy would seem to be an acceptable way of assessing efficacy of new AEDs in this population. Some regulators, however, do not accept equivalence as proof of efficacy and insist on demonstration of superiority compared to a control. The use of placebo alone in the control group is ethically dubious. Several innovative study designs have, therefore, been used to satisfy regulatory requirements, while maintaining patient safety including withdrawal to monotherapy using high versus low dose comparators. Observational outcome studies provide the best opportunity of exploring the long-term utility of individual AEDs. Such studies largely follow standard clinical practice and need considerable time and resources. They can, however, yield valuable information about the effectiveness of AEDs in everyday clinical practice. Data from regulatory trials should be complemented by postmarketing studies and longer term studies of outcome to help clinicians decide the best way of utilising new AEDs and establishing their role in the therapeutic armamentarium. 相似文献